The deletion and sequence mutations of CREBBP, which encodes the transcriptional coactivator and histone acetyltransferase (HAT) CREB-binding protein (CBP), have been reported in 18.3% of ALL relapse cases, and the mutations may confer resistance to therapy [20, 21]. The gene discussed is TMPRSS11D; the disease is acute lymphoblastic leukemia.